Lindsey Shapiro PhD, science writer —

Out-of-pocket costs for AstraZeneca’s inhaled respiratory therapies — most of which are used for chronic obstructive pulmonary disease (COPD) — will be capped at $35 per month for eligible patients in the U.S. starting in June, the company announced in a press release. This cap, likely to…

The U.S. Food and Drug Administration has agreed to review Sanofi and Regeneron Pharmaceuticals’ request for a label extension for Dupixent (dupilumab) to include it as an add-on treatment for certain adults with uncontrolled chronic obstructive pulmonary disease (COPD). The therapy’s potential sixth indication in the U.S.

The U.S. Food and Drug Administration (FDA) for the first time has cleared a fingertip pulse oximeter for home use as a medical device that consumers — including people with chronic obstructive pulmonary disease (COPD) — can use to check their blood oxygen levels. The device, MightySat Medical from…

Two international Phase 3 clinical trials testing the investigational antibody itepekimab in people with chronic obstructive pulmonary disease (COPD) are continuing to enroll patients — specifically, former smokers — at hundreds of centers worldwide, with several new sites recently opened in the U.S. All of the new sites are…

Treatment with Dupixent (dupilumab) — approved in the U.S. for five inflammatory conditions, to date — once again resulted in significantly fewer exacerbations, or periods of sudden symptom worsening, among people with moderate to severe chronic obstructive pulmonary disease (COPD) in the second of two similarly designed Phase 3…

Ensifentrine, an investigational medication under review in the U.S. for chronic obstructive pulmonary disease (COPD), is effective across key patient subgroups, including when patients are separated by their history of lung exacerbations and type of background therapy. That’s according to recent pooled analyses from the ENHANCE-1 (NCT04535986) and…

Increases in new onset or recurring depression were seen among older Canadian adults with chronic obstructive pulmonary disease (COPD) during the early stages of the COVID-19 pandemic, a study shows. One in six patients without a history of depression before the pandemic developed it early on in it. For…

Tiotropium bromide dry inhalation powder for use with the LupinHaler device, a generic version of Spiriva HandiHaler, is now available in the U.S. as a maintenance treatment of chronic obstructive pulmonary disease (COPD), Lupin Pharmaceuticals announced. Generics are considered bioequivalent to their brand-name alternatives,…

Breyna, a generic version of Symbicort (budesonide-formoterol), has been launched in the U.S. for eligible people with chronic obstructive pulmonary disease (COPD) and asthma. The inhaled medication — the first Symbicort generic to be approved by the U.S. Food and Drug Administration — will become immediately available…

Lower vitamin D levels in the blood are associated with an increased risk of chronic obstructive pulmonary disease (COPD), especially among smokers, according to a study looking at U.K. data. Adults with COPD who had lower vitamin D levels before their diagnosis were also at an increased mortality…